Barnaby Pickering
Reporter, Medtech Insight
Graduating in 2020 with a Master’s degree in biomedical engineering from University College London, Barnaby is passionate about all things medtech. In his first role as a journalist, Barnaby will focus on R&D and commercial stories in medtech, and writing about emerging technologies such as digital health, artificial intelligence, machine learning, deep-brain implants, and nanoscale applications of medtech. Alongside this, Barnaby is looking forward to taking deeper dives into start-ups, device market analysis, and company financial data, to create informed, useful, and engaging content.
Barnaby lives in in rural Wiltshire, UK and is a keen reader, cyclist, and hobbyist jeweler.
Latest From Barnaby Pickering
Boston Scientific TheraSphere Liver Cancer Treatment Succeeds In EPOCH Trial
Results showed that patients were less likely to exhibit disease progression, or die, following treatment with beta-emitted microspheres.
Pixee Medical Concludes Knee+ Study Highlighting Its Efficacy
A pilot study of the augmented reality system suggests it improves the precision of knee arthroplasty surgery.
Device Week, 16 September 2021 – AAOS Conference Wrap-up; Exciting New Diagnostic Method
In this week's podcast Medtech Insight’s Marion Webb gives a summary of this year’s American Academy Of Orthopedic Surgeons annual meeting, where she discusses new products from a range of companies, and interesting meetings with executives. UK-based reporter Barnaby Pickering sheds light on Owlstone Medical’s new diagnostic method, and managing editor Reed Miller highlights a story about the troubled Stereotaxis.
Flywheel.io Raises $22M And Buys Out Competition
A series C funding round will enable Flywheel.io to buy out Radiologics and continue development of its clinical trial data management products.
Stereotaxis Continues Its Turnaround, Bringing Robots To Endovascular Intervention
In an interview with Medtech Insight, Stereotaxis CEO David Fischel explained how the company intends to continue its recovery after a troubled near decade of decline.
Owlstone Medical Secures Funding To Develop Its Breath Biopsy Technology
The oversubscribed $58m funding round will enable the company to further work on its first-in-class breath biopsy technology, which aims to provide a cheap and convenient screening tool for several diseases.